Maternal serum free-β-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13+6 weeks in relation to co-variables in pregnant Saudi women

Prenatal Diagnosis

Volumn 27, Issue 4, 2007, Pages 303-311

  Ardawi, Mohammed Salleh M ^a   Nasrat, Hasan A ^a   Rouzi, Abdulrahim A ^a   Qari, Mohammed H ^a   Al Qahtani, Mohammed H ^a   Abuzenadah, Adel M ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Co variables; Fetal nuchal translucency; First trimester; Maternal serum screening

Indexed keywords

CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MATERNAL AGE; MATERNAL SMOKING; NUCHAL TRANSLUCENCY MEASUREMENT; PARITY; PREDICTOR VARIABLE; PREGNANCY; PRIORITY JOURNAL; SAUDI ARABIA; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; BODY WEIGHT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; INFANT, NEWBORN; LINEAR MODELS; MALE; NORMAL DISTRIBUTION; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY, MULTIPLE; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; REFERENCE VALUES; REPRODUCTIVE HISTORY; SAUDI ARABIA; SEX FACTORS; SMOKING; TWINS;

EID: 34247170345     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1661     Document Type: Article

References (69)

1. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One-stop clinic for assessment of risk of trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
2. Chen M, Lam YH, Tang MH, et al. 2002. The effect of ethnic origin on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 22: 576-578.
3. Christiansen M, Larsen SO. 2001. Precision of risk in multidimensional likelihood ratio based screening with first trimester screening for Down's syndrome as a special case. J Med Screen 8: 61-64.
4. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. 2002. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester; a Scottish multicenter study. BJOG 109: 667-676.
5. De Biasio P, Siccardi M, Volpe G, Famularo L, Santi F, Canini S. 1999. First-trimester screening for Down Syndrome using nuchal translucency measurement with free [beta]-hCG and PAPP-A between 10 and 13 weeks of pregnancy - the combined test. Prenat Diagn 19: 360-363.
6. de Graaf IM, Cuckle HS, Pajkrt E, Leschor NJ, Bleker OP, van Lith JMM. 2000. Co-variables in first trimester maternal serum screening. Prenat Diagn 20: 186-189.
7. Demir R, Demir AY, Yinanc M. 1994. Structural changes in placental barrier of smoking mother: a quantitive and ultrastructural study. Pathol Res Pract 190: 656-667.
8. Eiben B, Glaubitz R. 2005. First-trimester screening: an overview. J Histochem Cytochem 52: 281-283.
9. Fortuny A, Borrell A, Casals E, Seres A, Sanches A, Soler A. 2005. First trimester aneuploidy screening combining biochemical and ultrasound markers. Ultrasound Rev Obstet Gynecol 5: 9-17.
10. Gonce A, Borrell A, Fortuny A, et al. 2005. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement? Prenat Diagn 25: 1156-1161.
11. Greco P, Loverno G, Vimercati A, Marzullo A, Caruso G, Selvaggi L. 1996. Pathological significance of first trimester fetal nuchal oedema. Prenat Diagn 16: 503-509.
12. Hui PW, Tang MHY, Ng EHY, Yeung WSB, Ho PC. 2006. Nuchal translucency in dichorionic twins conceived after assisted reproduction. Prenat Diagn 26: 510-513.
13. Jauniaux E, Burton GJ. 1992. The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 79: 645-648.
14. Koos BJ. 2006. First-trimester Screening: lessons from clinical trials and implementation. Curr Opin Obstet Gynecol 18: 152-155.
15. Krantz DA, Hallahan TW, Macri VJ, Macri JN. 2005. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program. Prenat Diagn 28: 635-640.
16. Krantz DA, Hallhan TW, Orlandi F, Buchanan P, Larsen JW, Macri JN. 2000. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 96: 207-213.
17. Lamm YH, Tang MHY, Lee CP, et al. 2001. The effect of fetal gender on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 21: 627-629.
18. Larsen SO, Wajdemann KR, Shalmi AC, Sundberg K, Christiansen M, Tabor A. 2002. Gender impact on first trimester markers in Down Syndrome screening. Prenat Diagn 22: 1207-1208.
19. Leung TY, Spencer K, Leung TN, Fung TY, Lau TK. 2006. Higher median levels of free beta-hCG and PAPP-A in the first-trimester of pregnancy in a Chinese ethnic group. Implication for first-trimester combined screening for Down's syndrome in the Chinse population. Fetal Diagn Ther 21: 140-143.
20. Malone FD, Canick JA, Ball RH, et al. 2005. First- and second-trimester evaluation of risk (FASTER) research consortium. First-trimester or second-trimester screening or both, for Down's syndrome. N Engl J Med 353: 2001-2011.
21. Marana HR, Andrade JM, Martins GA, Silva JS, Sala MA, Cunha SP. 1998. A morphometric study of maternal smoking on apoptosis in the syncytiotrophoblast. Int J Gynaecol Obstet 61: 21-27.
22. Mashiach R, Orr-Urtreger A, Yaron Y. 2004. A comparison between maternal serum free β-human chorionic gonadotrophin and pregnancy-associated plasma protein-A levels in first-trimester twin and singleton pregnancies. Fetal Diagn Ther 19: 174-177.
23. Maymon R, Neeman O, Shulman A, Rosen H, Herman A. 2005. Current concepts of Down syndrome screening tests in assisted reproduction twin pregnancies: another double female. Prenat Diagn 25: 746-750.
24. Maymon R, Jauniaux E, Holmes A, Wiener YM, Dreazen E, Herman A. 2001. Nuchal translucency measurement and pregnancy outcome after assisted conception versus spontaneously conceived twins. Hum Reprod 16: 1999-2004.
25. Neveux LM, Palomaki GE, Larivee DA, Kinght GJ, Haddow JE. 1996. Refinements in managing maternal weight adjustment for prenatal screening results. Prenat Diagn 16: 1115-1119.
26. Nicolaides KH. 2004. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 191: 45-67.
27. Nicolaides KH, Sebire NJ, Snijders RJM (eds). 1999. The 11-14 Weeks Scan. Parthenon Publishing: London.
28. Nicolaides KH, Heath V, Liao AW. 2000. The 11-14 week scan. Baillieres Best Pract Res Clin Obstet Gynecol 14: 581-594.
29. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2004. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-oriented two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
30. Niemimaa M, Heinonen S, Seppala M, Ryynanen M. 2003. The influence of smoking on the pregnancy associated plasma protein A, free β human chorionic gonadotrophin and nuchal translucency. Br J Obstet Gynecol 110: 664-667.
31. Niemimaa M, Suonpaa M, Heinonen S, Seppala M, Bloigu R, Ryynanen M. 2002. Maternal serum human chorionic gonadotropin and pregnancy-assocaited plasma protein A in twin pregnancies in the first-trimester. Prenat Diagn 22: 183-185.
32. Niemimaa M, Suonpaa M, Perheentupa A, et al. 2001. Evaluation of first trimester maternal serum and ultrasound screening for Down's Syndrome in Eastern and Northern Finland. Eur J Hum Genet 9: 404-408.
33. O'Brien JE, Dvorin E, Yaron Y, et al. 1997. Differntial increases in AFP, hCG, and uE3 in twin pregnancies: impact on attempts to quantity Down Syndrome screening calculations. Am J Med Genet 73: 109-112.
34. Odibo AO. 2005. First-trimester Screening for Down Syndrome. Postgrad Obstet Gynecol 25: 1-5.
35. O'Leary P, Breheny N, Dickinson JE, et al. 2006. First-trimester combined screening for Down Syndrome and other fetal anomalies. Obstet Gynecol 107: 869-876.
36. Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. 1997. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 10: 381-386.
37. Rozenberg P, Bussieres L, Chevret S, et al. 2006. Screening for Down Syndrome using first-trimester combined ultrasound followed by second-trimester ultrasound examination in unselected population. Am J Obstet Gynecol 195: 1379-1387.
38. Schuchter K, Hafner E, Stangl G, Metzenbauer M, Hofinger D, Philipp K. 2002. The first trimester 'combined test' for the detection of Down Syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 22: 211-215.
39. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1999. UK multicenter project on assessment of risk trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 18: 519-521.
40. Spencer K. 1999. The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy. Prenat Diagn 19: 1065-1066.
41. Spencer K. 2000. Screening for trisomy 21 in twin pregnancies in the first-trimester using free B-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 20: 91-95.
42. Spencer K. 2001. Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free beta-hCG or PAPP-A levels? Prenat Diagn 21: 715-717.
43. Spencer K, Nicolaides KH. 2002. A first-trimester Trisomy 13/Trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 22: 877-879.
44. Spencer K, Nicolaides KH. 2003. Screening for trisomy 21 in twin using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Br J Obstet Gynecol 110: 276-280.
45. Spencer K, Bindra R, Nicolaides KH. 2003a. Maternal weight correction of maternal serum PAPP-A and free β-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 23: 851-855.
46. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003b. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in one-stop clinic: a review of three years prospective experience. Br J Obstet Gynecol 110: 281-286.
47. Spencer K, Bindra R, Cacho AM, Nicolaides KH. 2004. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 24: 169-173.
48. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-hCG chorionic gonadotrophin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
49. Spencer K, Spencer CE, Power M, et al. 2000a. One-stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynecol 107: 1271-1275.
50. Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH. 2000b. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 411-416.
51. Spencer K, Liao AWJ, Skentou H, Ciero S, Nicolaides KH. 2000c. Screening for triploidy by fetal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 495-499.
52. Spencer K, Ong CY, Liao AW, Nicolaides KH. 2000d. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. Prenat Diagn 20: 792-794.
53. Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides K. 2000e. The influence of fetal sex in screening for tisomy 21 by nuchal translucency, maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 673-675.
54. Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH. 2000f. First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status. Prenat Diagn 20: 852-853.
55. Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. 2000g. The influence of ethic origin on first trimester biochemical markes of chromosomal abnormalities. Prenat Diagn 20: 491-494.
56. Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH. 2005. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first-trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn 25: 365-369.
57. Thilaganathan B, Khare M, Williams B, Wathen NC. 1998. Influence of ethnic origin on nuchal transluencey screening for Down's syndrome. Ultrasound Obstet Gynecol 12: 112-114.
58. Tsukerman GL, Gusina NB, Cuckle HS. 1999. Maternal serum screening for Down syndrome in the first trimester. Experience from Belarus. Prenat Diagn 19: 499-504.
59. Tul N, Spencer K, Noble P, Chan C, Nicolaides KH. 2000. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free betal hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19: 1035-1042.
60. Wald NJ, Hackshaw AK. 2000. Advances in antenatal screening for Down Syndrome. Baillieres Clin Obstet Gynecol 14: 563-580.
61. Wald NJ, Rodeck C, Hackshw AK, Walters J, Chitty L, Mackinson Am. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56-104.
62. Wapner R, Thom E, Simpson JL, et al, First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
63. Wenstrom KD. 2005. First-trimester Down Syndrome screening: component analytes and timing for optimal performance. Semin Perinatal 29: 195-202.
64. Wojdemann KR, Shalmi AC, Chrstiansen M, et al. 2005. Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 25: 227-233.
65. Wojdemann KR, Larsen SO, Shalmi A-C, Sundberg K, Tabor A, Christiansen M. 2006a. Nuchal translucency measurements are highly correlated in both mono- and dichorionic twin pairs. Prenat Diagn 26: 218-220.
66. Wojdemann KR, Larsen SO, Rode L, et al. 2006b. First-trimester Down Syndrome screening: distribution of markers and comparison of assays for quantification of pregnancy-associated plasma protein A. Scand J Clin Lab Invest 66: 101-112.
67. Yaron Y, Wolman I, Kupferminc MJ, Ochshorn Y, Many A, Orr-Urtreger A. 2001. Effect of fetal gender on first trimester markers and on Down syndrome screening. Prenat Diagn: 1027-1030.
68. Yaron Y, Lehavi O, Orr-Urtreger A, et al. 2002. Maternal serum hCG is higher in the presence of a female fetus as early as week 3 post-fertilization. Hum Reprod 17: 485-489.
69. Yigiter AB, Navak ZN, Bakirci N, Gokaslan H. 2006. Effect of smoking on pregnancy-assocaited plasma protein A, free β-human chorionic gonadotrophin, and nuchal translucency in the first trimester of pregnancy. Adv Ther 23: 131-138.